Interim Report May-January 2018/2019
Significant events during the third quarter · Abstract was presented at San Antonio Breast Cancer Symposium · New office and staff in USA Significant events after the end of the period · Abstract to be presented at AACR in April · Shares now traded on Nasdaq First North Premier · Lars Holmqvist elected as new Chairman · Two new customers, a pharmaceutical company and a CRO, and sales of SEK 1.5 million.CEO’s comments Continued focus on commercialization of DiviTum® The focus of Biovica’s business plan is commercialization of DiviTum®, which will provide cancer